Organogenesis (ORGO) CCO exercises option, now holds 900,682 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Organogenesis Holdings Inc. Chief Commercial Officer Brian Grow exercised stock options to acquire 958 shares of Class A Common Stock on January 10, 2025 at $1.24 per share. The option was fully vested and, after the transaction, he directly holds 900,682 shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
958 shares exercised/converted
Mixed
2 txns
Insider
Grow Brian
Role
Chief Commercial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 958 | $0.00 | -- |
| Exercise | Class A Common Stock | 958 | $1.24 | $1K |
Holdings After Transaction:
Stock Option (Right to Buy) — 0 shares (Direct, null);
Class A Common Stock — 900,682 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Shares acquired via option exercise: 958 shares
Exercise price: $1.24 per share
Shares held after transaction: 900,682 shares
+2 more
5 metrics
Shares acquired via option exercise
958 shares
Class A Common Stock acquired on January 10, 2025
Exercise price
$1.24 per share
Conversion or exercise price of stock option
Shares held after transaction
900,682 shares
Total direct Class A Common Stock after exercise
Option shares exercised
958 shares
Stock Option (Right to Buy) underlying shares
Option expiration date
January 12, 2025
Expiration date of the exercised stock option
Key Terms
Stock Option (Right to Buy), Exercise or conversion of derivative security, Class A Common Stock, Form 4
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Exercise or conversion of derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
Class A Common Stock financial
"security_title: "Class A Common Stock""
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
Form 4 regulatory
"INSIDER FILING DATA (Form 4):"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
What insider transaction did Organogenesis (ORGO) report for Brian Grow?
Brian Grow exercised stock options to acquire 958 shares of Organogenesis Class A Common Stock at $1.24 per share. This Form 4 shows a routine option exercise, increasing his directly held stake without any open-market buying or selling.
What was the exercise price of Brian Grow’s Organogenesis (ORGO) stock option?
The exercised stock option had a conversion or exercise price of $1.24 per share for 958 underlying shares. Exercising at this price converted the derivative position into common stock, as reflected in the Form 4’s non-derivative and derivative transaction entries.
What does the footnote on Brian Grow’s Organogenesis (ORGO) option say?
The footnote states that 100% of the shares subject to the option are fully vested and exercisable. This means all 958 option shares were already earned under the plan and could be exercised, consistent with the reported derivative conversion on the transaction date.